

Speakers



Marieke van Dalen MARA Consultancy, The Netherlands



Alma Kiso European Directorate for the Quality of Medicines (EDQM & Health Care), France



Cristina Jimenez Sala Centrient Pharmaceuticals, Spain



Dr Wilhelm Schlumbohm Berlin, Germany



GMP Certification Programme Certified Regulatory Affairs Manager

Global Registration and Life Cycle Management of APIs

21 – 23 April 2026 | Heidelberg, Germany



Regulatory API information and Changes thereto

Highlights

- Dossier Requirements for the Drug Substance
- Requirements for the Certificate of Suitability
- ASMF Procedure
- Synthesis derived Impurities, Genotoxic Impurities, Elemental Impurities and Residual Solvents
- Stability Data
- How to read and use a CEP / Implementation of CEP 2.0
- Choice and Justification of the API Starting Material in a Submission
- Variations/Changes and Life Cycle Management
- Registration Procedures in the US and Japan
- Regulatory Procedures in Brazil and China

Two Workshops

- Stability Studies and Establishing the Retest Date
- Description of the Manufacturing Process

Objectives

This education course is intended to provide guidance on the format, content and submission procedures for the pharmaceutical documentation of the quality of the drug substance for different types of dossiers, the CTD, the CEP and the European ASMF. In this context the consequences of the guidelines on Elemental Impurities (ICH Q3D (R1)) and genotoxic impurities (ICH M7) will be considered. Furthermore, the impact of the amended Variations Regulation will be discussed.

Participants will have the opportunity to take part in 2 work-shops:

- Stability studies and establishing a retest date
- Description of the manufacturing process

Background

In Europe there are several ways to document the quality of the drug substance for the purpose of marketing authorisation:

- Certificate of Suitability of the pharmacopoeial monograph (CEP)
- Full details of manufacture (according to CTD Module 3 Quality of Drug Substance)
- European Active Substance Master File (ASMF; former Drug Master File, DMF)
- Other evidence of suitability of the pharmacopoeial monograph

In the US, the quality of the drug substance can be documented as part of the CMC Dossier or in a US-DMF.

Target Audience

The education course is designed for all persons involved in the compilation of pharmaceutical dossiers for marketing authorisations who want to become familiar with the different ways to document the quality of the drug substance for the purpose of marketing authorisation in Europe. Furthermore, the course will be of interest to personnel from Quality Units of the medicinal products and the API industry.

Programme

Dossier Requirements for the Drug Substance – An Introduction

- Chemical pharmaceutical documentation for active substance(s) – Regulatory requirements in EU and USA
- Types of active substances types of documentation
- CTD Module 3, CEP and ASMF
- CEP for a substance for TSE risk assessment

Requirements for the Certificate of Suitability to the European Pharmacopoeia

- CEP Procedure: legal framework, the role, place and scope
- How the CEP procedure works for new CEPs
- Basic principles for maintaining the CEP: administrative, minor and major changes, renewal of CEPs
- Key figures and how to communicate with EDQM

The European Active Substance Master File Procedure

- Regulatory background and scope
- The revised European ASMF guideline
- Applicants' and restricted parts points to consider
- Questions & answers on the ASMF procedure
- Recent European developments: Sharing of assessment reports, data bases

Pharmaceutical Impurities: Residual Solvents, Synthesis-derived and Genotoxic and Elemental Impurities

- CPMP-/ICH-Guidelines on Impurities and Residual Solvents
- ICH M7 Guideline on genotoxic impurities
- ICH Q3D(R1) Guideline on elemental impurities
- Specifying impurities
- Classifying solvents, setting and proving limits
- Justification of specification

Stability Data

- CPMP/ICH Guidelines
- Stability Summary and conclusions, stability commitment
- Documentation of Stability Data
- Necessity for documentation of raw data?

How to read and use a CEP / Implementation of CEP 2.0

- How to interpret information laid down on CEP-practical examples
- Project CEP 2.0: What has changed and what are the benefits?
- CEP holders' responsibilities towards their customers
- How to use a CEP in marketing authorization application

API Regulatory Starting Materials

- Why is this such a hot topic
- What guidelines to consider
- How to define a suitable starting material
- How to defend your choice in the submission
- What is different for generics
- Consequences of a redefinition

Top Ten Deficiencies in new Applications for Certificates of Suitability for Chemical Purity

- CEP process overview with focus on technical validation at reception
- How to build up a successful dossier and avoid deficiencies
- Top 10 most frequent question raised after the initial assessment of new applications for CEP with practical examples
- Expectations and recommendations on how to address the specific deficiencies with reference to applicable guidelines

Comparison of the CEP and DMF Procedure

- Advantages of the CEP procedure
- Handling Changes
- In which countries is the CEP being accepted?
- Cost considerations
- Practical examples

Regulatory Procedures in the US and Japan

- Overview of the procedures
- Specifics for US and Japan

The EDQM Inspection Programme

- How does the EDQM inspection procedure work
- EDQM GMP Assessment tools: On-site inspections, documentation-based GMP Assessment and Real Time Remote Inspections (RTEMIS)
- Inspection facts and figures
 - Stability Studies and Establishing the Retest Date
 Cristina Jimenez Sala
 - Description of the Manufacturing Process
 Dr Wilhelm Schlumbohm

Important: In order to prepare the lectures and the workshops in an optimal way, please send your questions to special topics to Ms Anne Günster, <u>guenster@concept-heidelberg.de</u>. She will forward your questions to the responsible speaker. Thank you in advance for your cooperation.

Country specific Requirements

- General remarks on API registrations in Emerging Countries
- Details of API registration in:
 - Taiwan
 - India
 - CIS countries: Russia, Belarus, Ukraine
 - GCC countries
 - APIC Emerging Countries Interest Group

Regulatory Procedures in Brazil and China

- Overview of the procedures
- Specifics for Brazil and China
- Experiences

Variations/Changes and Life Cycle Management

- Types and categories of API changes
- EU: the variation regulation and CEP revisions
- Handling API changes in the US
- Handling API changes in Japan
- Handling API changes outside these regions
- Initiatives to facilitate changes

Speakers

Marieke van Dalen, MARA Consultancy, The Netherlands Ms van Dalen is a global API regulatory specialist leading her own small consultancy in the Netherlands. She has 38 years of experience in the API industry, always in the regulatory field. Her latest position was with Aspen API in the Netherlands, as Global Regulatory Specialist. She was for a long time a Board member of APIC (the European API organisation) and represented APIC often in meetings and symposia with health Authorities all around the world.

Alma Kiso, Certification of Substances Department, European Directorate for the Quality of Medicines and Healthcare (EDQM), France

Ms Kiso, BSc, MSc, is a Scientific Officer in the Certification Department of the EDQM. Before joining the EDQM, she was in charge of assessment of new applications for marketing authorisation for medicinal products for human use with the Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina. She was also member of the European Pharmacopoeia Commission and expert group P4 within Ph. Eur. Commission. Since October 2016, Alma Kiso is in charge of the evaluation of new applications for Certificate of Suitability (CEP) in the Certification Department.

Cristina Jimenez Sala, Centrient Pharmaceuticals, Spain

Ms Jiménez is a pharmacist and holds a master's degree in Pharmaceutical Industry. She has been working on different regulatory affairs positions dedicated to the life cycle management of the dossiers for final dosage forms and active principle ingredients for internal and external customers. Additionally, she was also involved in registration procedures for different type of medical devices and in vitro diagnostic products. The last years she was specially focused on managing documentation for sterile APIs registered all over the world, including FDA, EDQM, Korea, Taiwan, India, Singapore and South Africa among others.

Dr Wilhelm Schlumbohm, Berlin, Germany

Dr Schlumbohm worked 30 years with German drug licensing authorities. He was an expert for the Certification Procedure of the European Pharmacopoeia and a member of the TAB for several years. He was also a member of the ASMF working group, and the CVMP co-opted member for quality. He is a pharmacist, holds a Ph D in biochemistry, and is further qualified as pharmacist for drug information and for public health.

If the bill-to-address deviates from the specifica- Reservation Form (Please complete in full) tions on the right, please fill out here: Global Registration and Life Cycle Management of APIs 21 – 23 April 2026, Heidelberg, Germany	Title, first name, surname	Department Company	Important: Please indicate your company's VAT ID Number Purchase Order Number, if applicable	CONCEPT HEIDELBERG P.O. Box 101764 Country Country	Fax +49 (0) 62 21/84 44 34	D-69007 Heidelberg GERMANY E-Mail (Please fill in)	General terms and conditions CONCEPT HEIDELBERG reserves the right to change the materials, instructors, us in writing. The cancellation fee will then be calculated according to the point Privacy Policy: By registering for this event, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this event, l accept the processing of this order, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this event, l accept the processing of this order, and processing of this order, registration fee, wen'f Privacy Policy: By registering for this event, l accept the processing of this order, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this event, l accept the processing of this order, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this event, l accept the processing of this order, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this processing of this order, l accept the processing of this order, registration fee, wen'f Privacy Policy: By registering for this processing of this order, l accept the processing of this order or and registration fee which here cancel entrievely uset and will receive a full registration fee where the two processing fees: Privacy Policy: L accept the processing of this order, l accept the processing of this order or and received or the reaction or and received or the reaction order or and received or the reaction or detector ordetector). Privacy Policy: L accorept the
If the bill-to-address deviates from th tions on the right, please fill out here:				CONCEPT HEIDELE P.O. Box 101764	Fax +49 (0) 62 21/8	D-69007 Heidelber GERMANY	General terms and conditions If you cannot attend the conference you have two options: 1. We are happy to welcome a substitute colleague at any time. 2. If you have to cancel entirely we must charge the following processing fees: - Cancellation until 4 weeks prior to the conference 20 %, - Cancellation until 2 weeks prior to the conference 25 %,

Reservation Form (Please complete in full)

Date

Tuesday, 21 April 2026, 09.00 - 17.30 CEST (Registration and coffee 8.30 – 9.00) Wednesday, 22 April 2026, 09.00 - 17.30 CEST Thursday, 23 April 2026, 08.30 – 15.00 CEST

Venue

NH Collection Heidelberg Bergheimer Straße 91, 69115 Heidelberg, Germany Phone: +49 6221 1327 0 eMail: nhcollectionheidelberg@nh-hotels.com

Fees (per delegate, plus VAT)

ECA Members € 2,290 | APIC Members € 2,390 Non-ECA Members € 2,490 | EU GMP Inspectorates € 1,245 The fee is payable in advance after receipt of invoice and includes social event on the first day, lunch on all three days and all refreshments. VAT is reclaimable.

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form/ POG when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax – or search and register directly at www.gmp-compliance.org under the number 22233.

Conference language

The official conference language will be English.

Presentations/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.

Social Event



On the evening of the first day, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event. CONCEPT HEIDELBERG P.O. Box 10 17 64, D-69007 Heidelberg Telefon +49(0) 62 21/84 44-0, Telefax +49(0) 62 21/84 44 34 info@concept-heidelberg.de www.concept-heidelberg.com

For questions regarding content please contact: Ms Anne Günster (Operations Director) at +49(0)62 21/84 44 50, or per e-mail at guenster@concept-heidelberg.de.

For questions regarding organisation etc. please contact: Ms Nicole Bach (Organisation Manager) at +49(0)62 21/84 44 22, or per e-mail at nicole.bach@concept-heidelberg.de.